Clobetasol 0.05% Treatment Protocol for Limited‑Area Plaque Psoriasis

Formulation Selection

Body/trunk plaques – Use a cream or ointment formulation for optimal delivery to non‑hair‑bearing skin. (American Academy of Dermatology) 3
Scalp plaques – Prefer solution, foam, or spray formulations because they penetrate hair‑bearing areas more effectively. (Practice guideline) 1
Foam – Achieves a 74 % rate of clear or almost clear scalp lesions when applied twice daily for 2 weeks. (Practice guideline) 1

Initial phase (Weeks 1‑2) – Apply clobetasol propionate 0.05 % once daily to affected plaques. (Practice guideline) 1
Taper phase (Weeks 3‑4) – Switch to alternate‑day applications. (Practice guideline) 1
Maintenance phase (Weeks 5‑8) – Apply twice weekly; total continuous treatment must not exceed 4 weeks. (Practice guideline) 1
Maximum amount – Do not exceed 50 g per week for any formulation. (Practice guideline) 1

Beyond 2 weeks of daily use – Significantly raises risk of skin atrophy, striae, telangiectasia, and hypothalamic‑pituitary‑adrenal (HPA) axis suppression. (Practice guideline) 1
Beyond 4 weeks of use – Dramatically increases both cutaneous side‑effects and systemic absorption. (Practice guideline) 1
High‑risk sites – Avoid application to the face and intertriginous (skin‑fold) areas because they are most prone to adverse effects. (Practice guideline) 1

Overall response – Between 58 % and 92 % of patients achieve a clinically significant improvement with clobetasol therapy. (Practice guideline) 2
Scalp disease – 81 % attain ≥50 % lesion clearance after 2 weeks of twice‑daily solution application. (Practice guideline) 1

Apply a thin layer only to the plaques; do not spread onto surrounding normal skin. (Practice guideline) 1
Leave on continuously between applications; do not wash off the medication. (Practice guideline) 1
One fingertip unit (≈0.5 g) covers an area roughly twice the size of an adult palm. (Practice guideline) 1

Local adverse effects – Skin atrophy, striae, telangiectasia, folliculitis, and purpura are most common with prolonged use. (Practice guideline) 1
Systemic adverse effects – HPA‑axis suppression can occur when >50 g/week is used or when large body‑surface areas are treated. (Practice guideline) 2
Tachyphylaxis – Loss of therapeutic effectiveness may develop with extensive continuous use. (Practice guideline) 1
Scalp‑specific – Folliculitis is the most frequent adverse event with scalp application. (Practice guideline) 1

Body‑surface‑area >10 % – Indicates disease beyond the “limited‑area” definition and warrants systemic treatment. (Practice guideline) 4
Inadequate response after 4 weeks of appropriate topical therapy. (Practice guideline) 1
Need for continuous high‑potency corticosteroid beyond 4 weeks to maintain control. (Practice guideline) 1

Tazarotene 0.1 % gel combined with a medium‑ or high‑potency corticosteroid (e.g., clobetasol) enhances efficacy and prolongs remission for 8‑16 weeks. (American Academy of Dermatology) 3